1. Scrip
  2. >>Business

Galloping India Growth For Sacubitril/Valsartan Under Shadow Of Challenge

 
• By Anju Ghangurde

Sacubitril/valsartan combination sales surge in India driving growth in the cardiac care segment even as Novartis and challenger Natco slug it out in court over alleged patent infringement charges.  

Horses
Indian market for sacubitril/valsartan grows sharply • Source: Shutterstock

The Indian market for the sacubitril/valsartan combination appears to be growing in leaps and bounds, suggesting that Novartis AG’s efforts to expand reach and access for its heart failure therapy via partnerships is paying dividends. Nevertheless, the shadow of an ongoing suit for a cut-price version of the product looms.

Novartis’s Entresto (sacubitril/valsartan) is sold as Vymada in India, along with its second brands Cidmus and Azmarda, marketed by Lupin Ltd. and Cipla Ltd., respectively. Natco Pharma Ltd. earlier this year introduced its valsartan/sacubitril combination (Valsac)) at risk, with Novartis moving court against the Indian company for allegedly infringing its Indian patent on the product

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

BeiGene To Trade Beach For Chalet In Swiss Redomiciling As BeOne

 
• By Alaric DeArment

The biotech saw a slight quarter-over-quarter decline in sales from the BTK inhibitor Brukinsa, which it attributed to seasonality, while revenues overall missed some analyst estimates.

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

More from Scrip

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.